Biomind Labs Inc.
BMND
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -59.96% | -78.59% | -78.39% | -70.71% | -72.37% |
| Depreciation & Amortization | -66.33% | -76.68% | -82.63% | -78.15% | -51.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.74% | -79.97% | -73.60% | -66.17% | -62.85% |
| Operating Income | 71.74% | 79.97% | 73.60% | 66.17% | 62.85% |
| Income Before Tax | 51.50% | 64.65% | 65.11% | 60.81% | 66.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.50% | 64.65% | 65.11% | 60.81% | 66.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.50% | 64.65% | 65.11% | 60.81% | 66.88% |
| EBIT | 71.74% | 79.97% | 73.60% | 66.17% | 62.85% |
| EBITDA | 71.94% | 80.55% | 73.93% | 66.40% | 62.94% |
| EPS Basic | 52.06% | 64.78% | 65.19% | 60.93% | 67.01% |
| Normalized Basic EPS | 50.82% | 63.83% | 64.60% | 60.63% | 66.76% |
| EPS Diluted | 52.06% | 64.78% | 65.19% | 60.93% | 67.01% |
| Normalized Diluted EPS | 50.82% | 63.83% | 64.60% | 60.63% | 66.76% |
| Average Basic Shares Outstanding | 0.91% | 0.00% | 0.00% | 0.00% | 0.09% |
| Average Diluted Shares Outstanding | 0.91% | 0.00% | 0.00% | 0.00% | 0.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |